Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643617 · ClinicalTrials.gov registry record · NA
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
A NA study of Prostate Cancer and Prostatic Neoplasms, sponsored by Accuray Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 307
- Enrollment target
- 18
- Study locations
NCT00643617: Completed NA study of Prostate Cancer and Prostatic Neoplasms, sponsored by Accuray Incorporated.
NCT00643617 is a NA study of Prostate Cancer and Prostatic Neoplasms that has completed, run by Accuray Incorporated. The registered enrollment target is 307 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643617, a NA study of Prostate Cancer and Prostatic Neoplasms, has completed, sponsored by Accuray Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 307 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
Primary Outcome
To estimate the rates of acute and late Grade 3-5 gastrointestinal and genitourinary toxicities (adverse events \[AE\]) observed in both low-risk and intermediate-risk cohorts during the 5 years following CyberKnife (CK) treatment for prostate cancer. Kaplan Meier estimates for 5-yr and 10-yr are reported. Adverse events occurring within 3 months of treatment were categorized as acute toxicities, and those developing after 3 months were considered late toxicities. The rates were determined usi
Conditions Studied
Interventions
- RADIATION CyberKnife Stereotactic Radiosurgery - Low Risk
- RADIATION CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Study Locations (18)
California
- Community Regional Medical Center - Fresno
- Long Beach Memorial Medical Center - Long Beach
- Pasadena Cyberknife Center - Pasadena
- CyberKnife Centers of San Diego - San Diego
Florida
- New Millenium CyberKnife - Brandon
- JFK Comprehensive Cancer Center - Lake Worth
- South Florida Radiation Oncology - Wellington
Colorado
- Penrose Cancer Center - Colorado Springs
- Colorado Cyberknife - Lafayette
Alabama
- Mitchell Cancer Center University of South Alabama - Mobile
Illinois
- Elmhurst Memorial Hospital - Elmhurst
Montana
- Benefis Health System - Sletten Cancer Institute - Great Falls
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New Jersey
- AtlantiCare Regional Medical Center - Egg Harbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2007-10-22 |
| Est. Completion | 2022-04-07 |
| Phase | NA |
What the finished NCT00643617 record still lists
NCT00643617 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower).
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which CyberKnife Stereotactic Radiosurgery - Low Risk is the first listed.
NCT00643617 lists 18 locations in 12 states (California, Florida, Colorado).
Frequently Asked Questions
What is clinical trial NCT00643617 about?
NCT00643617 is a clinical study titled "CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry". The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
What is the current status of trial NCT00643617?
This trial is currently completed. It is a NA study. The enrollment target is 307 participants. The study started on 2007-10-22. Estimated completion is 2022-04-07.
What conditions does trial NCT00643617 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate, Prostatic Cancer, Prostate Neoplasms.
What interventions are being tested in trial NCT00643617?
The interventions under investigation include: CyberKnife Stereotactic Radiosurgery - Low Risk (RADIATION), CyberKnife Stereotactic Radiosurgery - Intermediate Risk (RADIATION).
Who is sponsoring clinical trial NCT00643617?
This trial is sponsored by Accuray Incorporated, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00643617 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00643617's enrollment target sits among peer trials
307 155th of 735 higher than 581 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI